Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held by Castle Biosciences, Inc. on May 28, 2026. The filing details the voting outcomes for four specific proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on the following matters:
- Proposal 1: Election of Directors - Three Class I Directors were elected to serve until the 2029 annual meeting:
- Ellen Goldberg: 15,455,265 For; 7,118,166 Withhold.
- Miles D. Harrison: 15,607,369 For; 6,966,062 Withhold.
- Tiffany P. Olson: 14,380,655 For; 8,192,776 Withhold.
- Proposal 2: Ratification of Auditor - Stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Results: 24,531,366 For; 445,666 Against.
- Proposal 3: Executive Compensation - Stockholders approved, on an advisory basis, the compensation of Named Executive Officers. Results: 21,280,180 For; 1,281,394 Against.
- Proposal 4: Director Compensation Policy - Stockholders approved the Non-Employee Director Compensation Policy. Results: 21,394,330 For; 1,130,133 Against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the final voting percentages for the three Class I Director candidates, noting the significant number of "Withhold" votes relative to "For" votes.
- Confirm the appointment of KPMG LLP as the auditor for the fiscal year ending December 31, 2026.
- Review the definitive proxy statement filed on April 8, 2026, for details on the executive and director compensation policies approved.
- Note the presence of 2,415,788 Broker Non-Votes on the director election and compensation proposals.